Internal consistency, construct validity, and responsiveness of the MRC Prion Disease Rating Scale
These findings provide strong preliminary evidence that the MRC-PDRS is reliable, valid, and responsive as a tool for measuring disease progression in patients with prion disease, with preliminary MIC estimates ranging from 1 to 3 points. This supports the use of MRC-PDRS in evaluating potential treatment benefits of prion disease clinical trials, and potentially in clinical practice settings.
Authors
- Aaron Yarlas (ORCID: https://orcid.org/0000-0003-4600-259X)
- R. Dario Pulido
- Kathleen Glisic
- J. Ludwig (ORCID: https://orcid.org/0000-0001-6248-1215)
- Brian S. Appleby (ORCID: https://orcid.org/0000-0003-2275-3292)
- Leah Leidy
Institutions
- University Hospitals of Cleveland (US)
- Ionis Pharmaceuticals (United States) (US)
- Case Western Reserve University (US)
- Florida Atlantic University (US)
Publication Details
- Journal
- Journal of Patient-Reported Outcomes
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1186/s41687-025-00884-3
- Citations
- 1
- Primary Topic
- Prion Diseases and Protein Misfolding
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Centers for Disease Control and Prevention